-Bloomberg The corpse of Indian farmer Bengali Singh burned to ash atop a blazing funeral pyre on the banks of the river Ganges in 2006. Five years later, the dead man was recorded as being paid by India's $33 billion rural jobs program to dig an irrigation canal in Jharkhand state. Officials in his village and the surrounding region used at least 500 identities, including those of Singh, a disabled child of...

-The Indian Express Chandigarh: Slamming the Punjab government for sponsoring "xenophobia", the Punjab and Haryana High Court on Wednesday set aside its "discriminatory" rules, wherein it had allowed additional weightage to rural students for government jobs. A Full Bench comprising Justices Hemant Gupta, Ajay Tewari and R N Raina held the rules framed by Punjab as "illegal, unconstitutional" and beyond its "legislative competence". "State sponsored xenophobia is constitutional anathema and the principle...

-The Business Standard CAG state audit report NCT has also unearthed a glaring lack of planning cutting across projects, sectors It may be India's capital city, but behind the New Delhi's storied corridors of power and flush coffers, the metropolis is a difficult mess for the ordinary citizen. The Comptroller and Auditor General's (CAG) state audit report for the National Capital Territory (NCT) of Delhi government has unearthed a series of significant shortcoming...

-The Economic Times Should drug companies make clinical trials data public? All over the world, drug regulators are increasingly in favour of doing so, much to the discomfort of pharmaceutical companies, and the London-based European Medicines Agency (EMA) is the first mover in this regard. As the journal Nature reports, EMA is likely to do so by next year, at least for some clinical trials data. On April 19, all the...

-The Economic Times Foreign pharma companies could be forced to overhaul their strategy for the Indian market by striking more local deals and cutting sky-high drug prices after the Supreme Court slammed the door on Swiss giant Novartis' attempts to gain a patent for its blood cancer-busting drug Glivec. But the ruling, welcomed by activists campaigning for affordable drugs and local generic companies, threatened to reinforce a narrative that India...